(Q44950901)

English

Sulfhydryl angiotensin-converting enzyme inhibition induces sustained reduction of systemic oxidative stress and improves the nitric oxide pathway in patients with essential hypertension

scientific article

In more languages

Statements

scholarly article

1 reference

Europe PubMed Central

7 December 2017

Sulfhydryl angiotensin-converting enzyme inhibition induces sustained reduction of systemic oxidative stress and improves the nitric oxide pathway in patients with essential hypertension (English)

1 reference

Europe PubMed Central

7 December 2017

0 references

1

1 reference

Europe PubMed Central

7 December 2017

6

object named as

L J Ignarro

1 reference

Europe PubMed Central

7 December 2017

author name string

V Sica

2

1 reference

Europe PubMed Central

7 December 2017

F de Nigris

3

1 reference

Europe PubMed Central

7 December 2017

O Pignalosa

4

1 reference

Europe PubMed Central

7 December 2017

M Condorelli

5

1 reference

Europe PubMed Central

7 December 2017

A Liguori

7

1 reference

Europe PubMed Central

7 December 2017

language of work or name

0 references

publication date

1 July 2004

1 reference

Europe PubMed Central

7 December 2017

American Heart Journal

1 reference

Europe PubMed Central

7 December 2017

148

1 reference

Europe PubMed Central

7 December 2017

1

1 reference

Europe PubMed Central

7 December 2017

e5

1 reference

Europe PubMed Central

7 December 2017

Oxidation-sensitive mechanisms, vascular apoptosis and atherosclerosis

1 reference

11 October 2022

https://opencitations.net/index/coci/api/v1/references/10.1016/J.AHJ.2004.03.025

Attenuation of atherosclerosis in apolipoprotein E-deficient mice by ramipril is dissociated from its antihypertensive effect and from potentiation of bradykinin

1 reference

11 October 2022

https://opencitations.net/index/coci/api/v1/references/10.1016/J.AHJ.2004.03.025

Role of oxidized low density lipoprotein in atherogenesis

1 reference

11 October 2022

https://opencitations.net/index/coci/api/v1/references/10.1016/J.AHJ.2004.03.025

Fatty streak formation occurs in human fetal aortas and is greatly enhanced by maternal hypercholesterolemia. Intimal accumulation of low density lipoprotein and its oxidation precede monocyte recruitment into early atherosclerotic lesions

1 reference

11 October 2022

https://opencitations.net/index/coci/api/v1/references/10.1016/J.AHJ.2004.03.025

Angiotensin II stimulates macrophage-mediated oxidation of low density lipoproteins

1 reference

11 October 2022

https://opencitations.net/index/coci/api/v1/references/10.1016/J.AHJ.2004.03.025

Abnormal endothelium-dependent vascular relaxation in patients with essential hypertension

1 reference

11 October 2022

https://opencitations.net/index/coci/api/v1/references/10.1016/J.AHJ.2004.03.025

Vitamin E supplementation and cardiovascular events in high-risk patients

1 reference

11 October 2022

https://opencitations.net/index/coci/api/v1/references/10.1016/J.AHJ.2004.03.025

Beneficial effects of ACE-inhibition with zofenopril on plaque formation and low-density lipoprotein oxidation in watanabe heritable hyperlipidemic rabbits

1 reference

11 October 2022

https://opencitations.net/index/coci/api/v1/references/10.1016/J.AHJ.2004.03.025

Low density lipoprotein isolated from patients with essential hypertension exhibits increased propensity for oxidation and enhanced uptake by macrophages: a possible role for angiotensin II

1 reference

11 October 2022

https://opencitations.net/index/coci/api/v1/references/10.1016/J.AHJ.2004.03.025

Oxidation of low-density lipoprotein in normotensive type 2 diabetic patients. Comparative effects of enalapril versus nifedipine: a randomized cross-over over study

1 reference

11 October 2022

https://opencitations.net/index/coci/api/v1/references/10.1016/J.AHJ.2004.03.025

Effects of the administration of an angiotensin-converting enzyme inhibitor during the acute phase of myocardial infarction in patients with arterial hypertension. SMILE Study Investigators. Survival of Myocardial Infarction Long-term Evaluation

1 reference

11 October 2022

https://opencitations.net/index/coci/api/v1/references/10.1016/J.AHJ.2004.03.025

Decreased low-density lipoprotein oxidation after repeated selective apheresis in homozygous familial hypercholesterolemia

1 reference

11 October 2022

https://opencitations.net/index/coci/api/v1/references/10.1016/J.AHJ.2004.03.025

Comparisons in vitro, ex vivo, and in vivo of the actions of seven structurally diverse inhibitors of angiotensin converting enzyme (ACE).

1 reference

11 October 2022

https://opencitations.net/index/coci/api/v1/references/10.1016/J.AHJ.2004.03.025

Does ADMA cause endothelial dysfunction?

1 reference

11 October 2022

https://opencitations.net/index/coci/api/v1/references/10.1016/J.AHJ.2004.03.025

Randomized, placebo-controlled trial of the angiotensin-converting enzyme inhibitor, ramipril, in patients with coronary or other occlusive arterial disease

1 reference

11 October 2022

https://opencitations.net/index/coci/api/v1/references/10.1016/J.AHJ.2004.03.025

1,4-Dihydropyridine calcium channel blockers inhibit plasma and LDL oxidation and formation of oxidation-specific epitopes in the arterial wall and prolong survival in stroke-prone spontaneously hypertensive rats

1 reference

11 October 2022

https://opencitations.net/index/coci/api/v1/references/10.1016/J.AHJ.2004.03.025

The Effect of the Angiotensin-Converting–Enzyme Inhibitor Zofenopril on Mortality and Morbidity after Anterior Myocardial Infarction

1 reference

11 October 2022

https://opencitations.net/index/coci/api/v1/references/10.1016/J.AHJ.2004.03.025

Inhibitors of angiotensin converting enzyme decrease early atherosclerosis in hyperlipidemic hamsters. Fosinopril reduces plasma cholesterol and captopril inhibits macrophage-foam cell accumulation independently of blood pressure and plasma lipids

1 reference

11 October 2022

https://opencitations.net/index/coci/api/v1/references/10.1016/J.AHJ.2004.03.025

Angiotensin II induces smooth muscle cell proliferation in the normal and injured rat arterial wall

1 reference

11 October 2022

https://opencitations.net/index/coci/api/v1/references/10.1016/J.AHJ.2004.03.025

Effects of the early ACE inhibition in diabetic nonthrombolyzed patients with anterior acute myocardial infarction

1 reference

11 October 2022

https://opencitations.net/index/coci/api/v1/references/10.1016/J.AHJ.2004.03.025

Renin-angiotensin system and atherothrombotic disease: from genes to treatment

1 reference

11 October 2022

https://opencitations.net/index/coci/api/v1/references/10.1016/J.AHJ.2004.03.025

Development and validation of a liquid chromatographic method for the determination of the related substances of ramipril in Altace capsules

1 reference

11 October 2022

https://opencitations.net/index/coci/api/v1/references/10.1016/J.AHJ.2004.03.025

Angiotensin II-modified LDL is taken up by macrophages via the scavenger receptor, leading to cellular cholesterol accumulation

1 reference

11 October 2022

https://opencitations.net/index/coci/api/v1/references/10.1016/J.AHJ.2004.03.025

Nitric oxide as a signaling molecule in the vascular system: an overview.

1 reference

11 October 2022

https://opencitations.net/index/coci/api/v1/references/10.1016/J.AHJ.2004.03.025

Study on the relationship between plasma nitrite and nitrate level and salt sensitivity in human hypertension : modulation of nitric oxide synthesis by salt intake

1 reference

11 October 2022

https://opencitations.net/index/coci/api/v1/references/10.1016/J.AHJ.2004.03.025

ACE inhibition with perindopril and atherogenesis-induced structural and functional changes in minipig arteries.

1 reference

11 October 2022

https://opencitations.net/index/coci/api/v1/references/10.1016/J.AHJ.2004.03.025

Ramipril administration to atherosclerotic mice reduces oxidized low-density lipoprotein uptake by their macrophages and blocks the progression of atherosclerosis

1 reference

11 October 2022

https://opencitations.net/index/coci/api/v1/references/10.1016/J.AHJ.2004.03.025

Nitric oxide and atherosclerosis

1 reference

11 October 2022

https://opencitations.net/index/coci/api/v1/references/10.1016/J.AHJ.2004.03.025

Chronic treatment with sulfhydryl angiotensin-converting enzyme inhibitors reduce susceptibility of plasma LDL to in vitro oxidation, formation of oxidation-specific epitopes in the arterial wall, and atherogenesis in apolipoprotein E knockout mice.

1 reference

11 October 2022

https://opencitations.net/index/coci/api/v1/references/10.1016/J.AHJ.2004.03.025

Fosinopril reduces ADP-induced platelet aggregation in hypertensive patients

1 reference

11 October 2022

https://opencitations.net/index/coci/api/v1/references/10.1016/J.AHJ.2004.03.025

Double-blind comparison between zofenopril and lisinopril in patients with acute myocardial infarction: results of the Survival of Myocardial Infarction Long-term Evaluation-2 (SMILE-2) study

1 reference

11 October 2022

https://opencitations.net/index/coci/api/v1/references/10.1016/J.AHJ.2004.03.025

Asymmetrical dimethylarginine, an endogenous nitric oxide synthase inhibitor, in experimental hypertension

1 reference

11 October 2022

https://opencitations.net/index/coci/api/v1/references/10.1016/J.AHJ.2004.03.025

Antiatherogenic effect of angiotensin converting enzyme inhibitor (benazepril) and angiotensin II receptor antagonist (valsartan) in the cholesterol-fed rabbits

1 reference

11 October 2022

https://opencitations.net/index/coci/api/v1/references/10.1016/J.AHJ.2004.03.025

Antiatherosclerotic and antioxidative effects of captopril in apolipoprotein E-deficient mice.

1 reference

11 October 2022

https://opencitations.net/index/coci/api/v1/references/10.1016/J.AHJ.2004.03.025

Antiatherogenic effect of captopril in the Watanabe heritable hyperlipidemic rabbit

1 reference

11 October 2022

https://opencitations.net/index/coci/api/v1/references/10.1016/J.AHJ.2004.03.025

Effect of calcium antagonist or beta blockade treatment on nitric oxide-dependent vasodilation and oxidative stress in essential hypertensive patients

1 reference

11 October 2022

https://opencitations.net/index/coci/api/v1/references/10.1016/J.AHJ.2004.03.025

Zofenopril inhibits the expression of adhesion molecules on endothelial cells by reducing reactive oxygen species.

1 reference

11 October 2022

https://opencitations.net/index/coci/api/v1/references/10.1016/J.AHJ.2004.03.025

Molecular plasticity of vascular wall during N(G)-nitro-L-arginine methyl ester-induced hypertension: modulation of proinflammatory signals.

1 reference

11 October 2022

https://opencitations.net/index/coci/api/v1/references/10.1016/J.AHJ.2004.03.025

ACE inhibitor quinapril reduces the arterial expression of NF-kappaB-dependent proinflammatory factors but not of collagen I in a rabbit model of atherosclerosis

1 reference

11 October 2022

https://opencitations.net/index/coci/api/v1/references/10.1016/J.AHJ.2004.03.025

Chronic treatment with nitric oxide-releasing aspirin reduces plasma low-density lipoprotein oxidation and oxidative stress, arterial oxidation-specific epitopes, and atherogenesis in hypercholesterolemic mice

1 reference

11 October 2022

https://opencitations.net/index/coci/api/v1/references/10.1016/J.AHJ.2004.03.025

Effect of vitamins C and E on progression of transplant-associated arteriosclerosis: a randomised trial

1 reference

11 October 2022

https://opencitations.net/index/coci/api/v1/references/10.1016/J.AHJ.2004.03.025

The use of antioxidant supplements in coronary heart disease

1 reference

11 October 2022

https://opencitations.net/index/coci/api/v1/references/10.1016/J.AHJ.2004.03.025

Influence of maternal hypercholesterolaemia during pregnancy on progression of early atherosclerotic lesions in childhood: Fate of Early Lesions in Children (FELIC) study

1 reference

11 October 2022

https://opencitations.net/index/coci/api/v1/references/10.1016/J.AHJ.2004.03.025

Low-density lipoprotein oxidation in essential hypertension

1 reference

11 October 2022

https://opencitations.net/index/coci/api/v1/references/10.1016/J.AHJ.2004.03.025

The effect of angiotensin-converting enzyme inhibition on endothelial function and oxidant stress

1 reference

11 October 2022

https://opencitations.net/index/coci/api/v1/references/10.1016/J.AHJ.2004.03.025

The angiotensin-converting enzyme inhibitor, fosinopril, and the angiotensin II receptor antagonist, losartan, inhibit LDL oxidation and attenuate atherosclerosis independent of lowering blood pressure in apolipoprotein E deficient mice.

1 reference

11 October 2022

https://opencitations.net/index/coci/api/v1/references/10.1016/J.AHJ.2004.03.025

Multiple role of reactive oxygen species in the arterial wall.

1 reference

11 October 2022

https://opencitations.net/index/coci/api/v1/references/10.1016/J.AHJ.2004.03.025

Nitric oxide-releasing drugs

1 reference

11 October 2022

https://opencitations.net/index/coci/api/v1/references/10.1016/J.AHJ.2004.03.025

Atherosclerosis. the road ahead

1 reference

11 October 2022

https://opencitations.net/index/coci/api/v1/references/10.1016/J.AHJ.2004.03.025

Comparison of zofenopril and lisinopril to study the role of the sulfhydryl-group in improvement of endothelial dysfunction with ACE-inhibitors in experimental heart failure

1 reference

11 October 2022

https://opencitations.net/index/coci/api/v1/references/10.1016/J.AHJ.2004.03.025

Effect of enalapril on survival in patients with reduced left ventricular ejection fractions and congestive heart failure

1 reference

11 October 2022

https://opencitations.net/index/coci/api/v1/references/10.1016/J.AHJ.2004.03.025

Antioxidant effects of angiotensin-converting enzyme (ACE) inhibitors: free radical and oxidant scavenging are sulfhydryl dependent, but lipid peroxidation is inhibited by both sulfhydryl- and nonsulfhydryl-containing ACE inhibitors

1 reference

11 October 2022

https://opencitations.net/index/coci/api/v1/references/10.1016/J.AHJ.2004.03.025

Protective effects of sulfhydryl-containing angiotensin converting enzyme inhibitors against free radical injury in endothelial cells.

1 reference

11 October 2022

https://opencitations.net/index/coci/api/v1/references/10.1016/J.AHJ.2004.03.025

Identifiers

10.1016/J.AHJ.2004.03.025

1 reference

Europe PubMed Central

7 December 2017

1 reference

Europe PubMed Central

7 December 2017

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q44950901&oldid=2059207216"